Matches in SemOpenAlex for { <https://semopenalex.org/work/W1837162593> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W1837162593 endingPage "21" @default.
- W1837162593 startingPage "1017" @default.
- W1837162593 abstract "To assess the toxicity and efficacy of high dose ifosfamide in stage IV NSCLC.In a previous trial, we have determined maximum tolerated dose for 3-days ifosfamide treatment by 3-weeks schedule as 9 g/m2 according to hematologic tolerance. We therefore set up a phase II to study the toxicity and efficacy of this schedule in chemotherapy naive metastatic NSCLC. Ifosfamide (+ mesna 1 g/m2) was administered by a two hour infusion (3 g/m2) for three days every three weeks. Patients received three mesna bolus infusions (1 g/m2) at 4, 8 and 12 hours after the end of ifosfamide infusion. Antitumoral efficacy was performed after 2 cycles and treatment could be pursued for responding patients until disease progression. From september 1995 to January 1997, 31 patients have been included in this study. Median age was 60.7 years +/- 1.33 (41-70) for 27 males and 4 females. Patients (pts) presented metastases in lung for 10 pts, bone for 10 pts, liver for 6 pts, adrenal for 4 pts and multiorgan metastatic localisation for 1 patient. Seven patients were unassessable: 1 lost for follow-up, 1 sudden death, 5 treatment interruptions before evaluation time and 3 toxic deaths (9.6%).neutropenia grade 4 (10 pts and 1 death), cardiotoxicity grade 4 (1 pt) and 2 deaths following neurotoxicity grade 4. We achieve 4 partial responses (13%, 95CI: 3.6-29.8), 10 progressive diseases (32.3%, 95CI: 16.7-51.4) and 10 stabilizations (32.3%, 95CI: 16.7-51.4). Median response duration was 91 days +/- 55 d. Median survival was 9.3 months, e.g. 280 days (8-863). Overall survival at one year is 48%.This modality of high dose ifosfamide is as effective as standard monotherapy schedules in stage IV NSCLC. Unexpected toxicities particularly hematological ones could be due to a short duration of fractionated treatment. Results in term of survival leads us to further evaluate ifosfamide monotherapy treatment on a 5-day schedule basis." @default.
- W1837162593 created "2016-06-24" @default.
- W1837162593 creator A5021741635 @default.
- W1837162593 creator A5029261283 @default.
- W1837162593 creator A5033220886 @default.
- W1837162593 creator A5037272278 @default.
- W1837162593 creator A5039623202 @default.
- W1837162593 creator A5040513765 @default.
- W1837162593 creator A5040544006 @default.
- W1837162593 creator A5068474273 @default.
- W1837162593 creator A5070861925 @default.
- W1837162593 creator A5072758102 @default.
- W1837162593 date "1999-12-01" @default.
- W1837162593 modified "2023-09-26" @default.
- W1837162593 title "[High-dose ifosfamide in patients with stage IV non-small cell lung cancer: phase II trial from the Groupe français de pneumo-cancérologie (GFPC)]." @default.
- W1837162593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10660695" @default.
- W1837162593 hasPublicationYear "1999" @default.
- W1837162593 type Work @default.
- W1837162593 sameAs 1837162593 @default.
- W1837162593 citedByCount "1" @default.
- W1837162593 crossrefType "journal-article" @default.
- W1837162593 hasAuthorship W1837162593A5021741635 @default.
- W1837162593 hasAuthorship W1837162593A5029261283 @default.
- W1837162593 hasAuthorship W1837162593A5033220886 @default.
- W1837162593 hasAuthorship W1837162593A5037272278 @default.
- W1837162593 hasAuthorship W1837162593A5039623202 @default.
- W1837162593 hasAuthorship W1837162593A5040513765 @default.
- W1837162593 hasAuthorship W1837162593A5040544006 @default.
- W1837162593 hasAuthorship W1837162593A5068474273 @default.
- W1837162593 hasAuthorship W1837162593A5070861925 @default.
- W1837162593 hasAuthorship W1837162593A5072758102 @default.
- W1837162593 hasConcept C126322002 @default.
- W1837162593 hasConcept C141071460 @default.
- W1837162593 hasConcept C2776256026 @default.
- W1837162593 hasConcept C2776694085 @default.
- W1837162593 hasConcept C2777063308 @default.
- W1837162593 hasConcept C2777506904 @default.
- W1837162593 hasConcept C2778239845 @default.
- W1837162593 hasConcept C2780376820 @default.
- W1837162593 hasConcept C29730261 @default.
- W1837162593 hasConcept C71924100 @default.
- W1837162593 hasConcept C90924648 @default.
- W1837162593 hasConceptScore W1837162593C126322002 @default.
- W1837162593 hasConceptScore W1837162593C141071460 @default.
- W1837162593 hasConceptScore W1837162593C2776256026 @default.
- W1837162593 hasConceptScore W1837162593C2776694085 @default.
- W1837162593 hasConceptScore W1837162593C2777063308 @default.
- W1837162593 hasConceptScore W1837162593C2777506904 @default.
- W1837162593 hasConceptScore W1837162593C2778239845 @default.
- W1837162593 hasConceptScore W1837162593C2780376820 @default.
- W1837162593 hasConceptScore W1837162593C29730261 @default.
- W1837162593 hasConceptScore W1837162593C71924100 @default.
- W1837162593 hasConceptScore W1837162593C90924648 @default.
- W1837162593 hasIssue "12" @default.
- W1837162593 hasLocation W18371625931 @default.
- W1837162593 hasOpenAccess W1837162593 @default.
- W1837162593 hasPrimaryLocation W18371625931 @default.
- W1837162593 hasRelatedWork W1984979578 @default.
- W1837162593 hasRelatedWork W2003208630 @default.
- W1837162593 hasRelatedWork W2139550043 @default.
- W1837162593 hasRelatedWork W2162870172 @default.
- W1837162593 hasRelatedWork W2357097748 @default.
- W1837162593 hasRelatedWork W2357585035 @default.
- W1837162593 hasRelatedWork W2361360140 @default.
- W1837162593 hasRelatedWork W2415498959 @default.
- W1837162593 hasRelatedWork W2428528889 @default.
- W1837162593 hasRelatedWork W1993277780 @default.
- W1837162593 hasVolume "86" @default.
- W1837162593 isParatext "false" @default.
- W1837162593 isRetracted "false" @default.
- W1837162593 magId "1837162593" @default.
- W1837162593 workType "article" @default.